Bactiguard Holding AB (publ) (BACTI-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bactiguard Holding AB (publ) (BACTI-B) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.43 Million ≈ $-799.91K USD) by net assets (Skr311.60 Million ≈ $33.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BACTI-B stock market capitalisation for the company's overall valuation and market capitalisation.
Bactiguard Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Bactiguard Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bactiguard Holding AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bactiguard Holding AB (publ) ranked by their cash flow conversion efficiency. Explore Bactiguard Holding AB (publ) cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bokwang Industry Co Ltd
KQ:225530
|
0.002x |
|
Urja Global Limited
NSE:URJA
|
-0.086x |
|
New Century Logistics (BVI) Limited Ordinary Shares
NASDAQ:NCEW
|
0.782x |
|
HLB Global Co Ltd
KO:003580
|
-0.045x |
|
Harmoney Corp Ltd
AU:HMY
|
0.514x |
|
Dreadnought Resources Ltd
AU:DRE
|
-0.014x |
|
Zee Media Corporation Limited
NSE:ZEEMEDIA
|
0.290x |
|
Osmanli Menkul Degerler AS
IS:OSMEN
|
-0.129x |
Annual Cash Flow Conversion Efficiency for Bactiguard Holding AB (publ) (2009–2025)
The table below shows the annual cash flow conversion efficiency of Bactiguard Holding AB (publ) from 2009 to 2025. View Bactiguard Holding AB (publ) (BACTI-B) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr314.93 Million ≈ $33.89 Million |
Skr-1.49 Million ≈ $-160.02K |
-0.005x | -106.20% |
| 2024-12-31 | Skr328.34 Million ≈ $35.33 Million |
Skr24.99 Million ≈ $2.69 Million |
0.076x | +151.36% |
| 2023-12-31 | Skr353.18 Million ≈ $38.01 Million |
Skr-52.33 Million ≈ $-5.63 Million |
-0.148x | -2498.76% |
| 2022-12-31 | Skr495.71 Million ≈ $53.35 Million |
Skr3.06 Million ≈ $329.52K |
0.006x | -53.91% |
| 2021-12-31 | Skr541.45 Million ≈ $58.27 Million |
Skr7.26 Million ≈ $780.86K |
0.013x | +612.72% |
| 2020-12-31 | Skr373.35 Million ≈ $40.18 Million |
Skr702.00K ≈ $75.55K |
0.002x | -98.65% |
| 2019-12-31 | Skr386.69 Million ≈ $41.61 Million |
Skr53.98 Million ≈ $5.81 Million |
0.140x | +410.15% |
| 2018-12-31 | Skr370.82 Million ≈ $39.91 Million |
Skr-16.69 Million ≈ $-1.80 Million |
-0.045x | -384.84% |
| 2017-12-31 | Skr387.11 Million ≈ $41.66 Million |
Skr6.12 Million ≈ $658.29K |
0.016x | +149.70% |
| 2016-12-31 | Skr390.33 Million ≈ $42.01 Million |
Skr-12.41 Million ≈ $-1.34 Million |
-0.032x | +36.16% |
| 2015-12-31 | Skr417.44 Million ≈ $44.92 Million |
Skr-20.79 Million ≈ $-2.24 Million |
-0.050x | +27.72% |
| 2014-12-31 | Skr518.71 Million ≈ $55.82 Million |
Skr-35.74 Million ≈ $-3.85 Million |
-0.069x | +78.45% |
| 2013-12-31 | Skr140.95 Million ≈ $15.17 Million |
Skr-45.07 Million ≈ $-4.85 Million |
-0.320x | -13.00% |
| 2012-12-31 | Skr144.60 Million ≈ $15.56 Million |
Skr-40.92 Million ≈ $-4.40 Million |
-0.283x | -1883.43% |
| 2011-12-31 | Skr187.86 Million ≈ $20.22 Million |
Skr-2.68 Million ≈ $-288.41K |
-0.014x | -107.36% |
| 2010-12-31 | Skr292.61 Million ≈ $31.49 Million |
Skr56.71 Million ≈ $6.10 Million |
0.194x | -22.88% |
| 2009-12-31 | Skr317.39 Million ≈ $34.16 Million |
Skr79.76 Million ≈ $8.58 Million |
0.251x | -- |
About Bactiguard Holding AB (publ)
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management … Read more